CV Science

Mirjam Zeisel PhD, PharmD

Course and current status

CURRENT POSITION: Directrice de Recherche Inserm

Since 2025: Inserm U1350, Pathobiology and Therapy of Liver Diseases, IHU EVEREST, Lyon

Co-leading the team "Epigenetics, microenvironment and liver diseases" (2025-)

2017-2024: Inserm U1052, Cancer Research Center Lyon

Co-leading the team "Epigenetics, microenvironment and liver cancer" (2021-2024)

2009-2017: Inserm U1110, Institute of Viral and Liver Diseases, LabEx HepSYS, Strasbourg

Co-leading the group "Virus-host interactions and liver disease" (2011-2017)

PREVIOUS RESEARCH POSITIONS

Inserm U748, Institute of Virology, University Louis Pasteur, Strasbourg

Department of Medicine II, University Hospital Freiburg, Germany

Inserm U392, Faculty of Pharmacy, University Louis Pasteur, Strasbourg

Scientific summary

Virus-host interactions and liver disease

HCV and HBV are a major causes of hepatitis worldwide. Chronic viral hepatitis C or B may progress to liver cirrhosis and hepatocellular carcinoma (HCC). Efficient antiviral treatment and viral cure reduce but do not eliminate the risk of HCC development. Our research focuses on the characterization of virus host-interactions and the pathogenesis of viral infection. We are particularly interested in deciphering virus-induced alteration of regulatory networks involved in liver disease and cancer.